AccessibilityHelpAbout Us
Pt Kalbe Farma Tbk. logo

Pt Kalbe Farma Tbk.(OTC) PTKFY

Market Cap$2.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-43%
5 Year-44%
1 Year-43%
1 Month+6%
$8.90
+0.00%
+0.00Today
Pt Kalbe Farma Tbk. last closing stock price
MetricPriceDate
Last closeUSD 8.902026-09-08
Pt Kalbe Farma Tbk. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.18%USD 9.492026-09-01
1 month+6.21%USD 8.382026-08-07
3 month+6.54%USD 8.352026-06-09
Year to date-32.32%USD 13.152025-12-29
1 year-42.5%USD 15.482025-09-08
3 year-67.08%USD 27.042023-07-25
5 year-44.02%USD 15.902021-08-23
Since inception-42.87%USD 15.582012-08-06

Pt Kalbe Farma Tbk. Financials at a Glance

Market Cap

$2.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

IDR 37.91T

Net Income (TTM)

IDR 3.63T

EPS (TTM)

$0.94

P/E Ratio

9.42

Dividend

$0.22

Beta (Volatility)

0.20 (Low)

Price

$8.90

Volume

348

Open

$8.90

Previous Close

$8.90

Daily Range

$8.90 - $8.90

52-Week Range

$7.63 - $16.36

Estimated Earnings Date

Apr 28, 2026

PTKFY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pt Kalbe Farma Tbk.

PT Kalbe Farma Tbk is a leading pharmaceutical company in Indonesia, engaged in the development, distribution, and trading of a wide range of pharmaceutical products. The company operates through various divisions, including Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics.

Products and Services
  • Prescription Pharmaceuticals: Offers generic drugs, branded generics, and licensed drugs
  • Consumer Health: Includes over-the-counter drugs, food supplements, and energy drinks
  • Nutritionals: Provides a variety of nutritional products for all age groups
Growth Outlook
  • Revenue growth of 1.2% in Q2 2026 compared to Q1 2026
  • Net income increased by 7.5% in Q2 2026 year-over-year
  • Strong demand for health products supports long-term growth potential
Financial Highlights
  • TTM revenue of 39.5 trillion IDR, reflecting consistent performance
  • Net profit margin of 9.57% indicates effective cost management
  • Dividend yield of 2.5% offers attractive returns to shareholders
PT Kalbe Farma Tbk has established itself as a key player in the healthcare sector, with a diverse portfolio that caters to various consumer needs. The company's focus on innovation and quality has enabled it to maintain a competitive edge in the market. Recent financial performance shows a steady increase in revenue and net income, highlighting the company's resilience and ability to adapt to market demands. With a strong growth outlook and a commitment to delivering high-quality products, PT Kalbe Farma Tbk presents a compelling opportunity for potential investors interested in the pharmaceutical industry.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

12,806

CEO

Bernadette Ruth Setiady

Website

www.kalbe.co.id

Headquarters

Jakarta, JK 10510, ID

PTKFY Financials

Key Financial Metrics (TTM)

Gross Margin

37.52%

Operating Margin

12.07%

Net Income Margin

9.57%

Return on Equity

15.21%

Return on Capital

19.25%

Return on Assets

10.91%

Earnings Yield

10.62%

Dividend Yield

2.50%

Payout Ratio

25.07%

Stock Overview

Market Cap

$2.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

226.24M

Volume

348

Avg. Volume

394.048

Financials (TTM)

Gross Profit

IDR 14.12T

Operating Income

IDR 4.60T

EBITDA

IDR 5.39T

Operating Cash Flow

IDR 3.39T

Capital Expenditure

-IDR 886.22B

Free Cash Flow

IDR 2.50T

Cash & ST Invst.

IDR 5.01T

Total Debt

IDR 829.84B

Pt Kalbe Farma Tbk. Performance Analysis

Pt Kalbe Farma Tbk. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31IDR 1,953,905,5726.5%
20232023-12-31IDR 1,993,121,4202.0%
20242024-12-31IDR 2,055,931,5893.2%
20252025-12-31IDR 2,131,735,0623.7%
Pt Kalbe Farma Tbk. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.7%
Q42025-12-314.3%
Q12026-03-315.2%
Q22026-06-30-0.2%
Pt Kalbe Farma Tbk. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31IDR 0.983.5%
20232023-12-31IDR 0.78-20.3%
20242024-12-31IDR 0.8812.9%
20252025-12-31IDR 0.979.9%
Pt Kalbe Farma Tbk. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-24.2%
Q42025-12-3152.1%
Q12026-03-310.5%
Q22026-06-30-14.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

IDR 9.80T

+19.0%

Gross Profit

IDR 3.55T

+6.1%

Gross Margin

36.26%

N/A

Market Cap

$2.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$156.88K

N/A

Employees

12,835

N/A

Net Income

IDR 890.54B

-0.8%

EBITDA

IDR 1.39T

+6.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

IDR 5.01T

+26.7%

Total Debt

IDR 829.84B

+6.4%

Accounts Receivable

IDR 6.90T

+18.1%

Inventory

IDR 7.96T

+15.9%

Long Term Debt

IDR 176.72B

-14.2%

Short Term Debt

IDR 653.13B

+13.8%

Return on Assets

10.91%

N/A

Return on Invested Capital

17.23%

N/A

Free Cash Flow

IDR 847.74B

+5.0%

Operating Cash Flow

IDR 1.09T

+14.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MYCOFNoveris Health Sciences Inc.
$0.73+0.00%
TELIFTelescope Innovations Corp.
$0.36-4.45%
PFHOPacific Health Care Organization, Inc.
$1.03+0.00%
UEECUnited Health Products, Inc.
$0.04-19.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About PTKFY

What is the current price of Pt Kalbe Farma Tbk.?

Pt Kalbe Farma Tbk. is trading at $8.90 per share.

What is the 52-week range for Pt Kalbe Farma Tbk.?

Over the past 52 weeks, Pt Kalbe Farma Tbk. has traded between $7.63 and $16.36.

How much debt does Pt Kalbe Farma Tbk. have?

As of the most recent reporting period, Pt Kalbe Farma Tbk. reported total debt of IDR 46.14M.

How much cash does Pt Kalbe Farma Tbk. have on hand?

Pt Kalbe Farma Tbk. reported IDR 269.75M in cash and cash equivalents in its most recent financial results.

What is Pt Kalbe Farma Tbk.’s dividend yield?

Pt Kalbe Farma Tbk. currently has a dividend yield of 2.50%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services